Dashboard
1
Poor Management Efficiency with a low ROCE of 13.54%
- The company has been able to generate a Return on Capital Employed (avg) of 13.54% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of -5.98% and Operating profit at 7.66% over the last 5 years
4
With a fall in Net Sales of -38%, the company declared Very Negative results in Jun 26
5
With ROE of 28.74%, it has a fair valuation with a 3.23 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 20,506 Million (Large Cap)
11.00
NA
13.32%
-0.23
28.74%
2.73
Revenue and Profits:
Net Sales:
939 Million
(Quarterly Results - Jun 2026)
Net Profit:
221 Million
Total Returns (Price + Dividend) 
Company does not have enough history
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.98%
EBIT Growth (5y)
7.66%
EBIT to Interest (avg)
74.54
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.17
Sales to Capital Employed (avg)
0.85
Tax Ratio
15.00%
Dividend Payout Ratio
173.10%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
13.84%
ROE (avg)
15.94%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
3.23
EV to EBIT
25.93
EV to EBITDA
23.37
EV to Capital Employed
3.89
EV to Sales
4.54
PEG Ratio
NA
Dividend Yield
8.75%
ROCE (Latest)
15.01%
ROE (Latest)
28.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bearish
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
939.40
1,515.20
-38.00%
Operating Profit (PBDIT) excl Other Income
269.90
491.90
-45.13%
Interest
2.20
3.00
-26.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
220.50
423.10
-47.88%
Operating Profit Margin (Excl OI)
254.90%
304.60%
-4.97%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -38.00% vs 21.46% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -47.88% vs 1,291.83% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,858.30
7,230.90
-32.81%
Operating Profit (PBDIT) excl Other Income
1,038.50
890.70
16.59%
Interest
18.80
42.20
-55.45%
Exceptional Items
-117.50
-113.80
-3.25%
Consolidate Net Profit
2,110.70
2,215.20
-4.72%
Operating Profit Margin (Excl OI)
188.00%
105.40%
8.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -32.81% vs -11.44% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -4.72% vs 128.68% in Dec 2024
About Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd. 
Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






